Respiratory Inhalers Market, 2025: GSK, Novartis, Boehringer Ingelheim, Cipla, and AstraZeneca Dominate the Market

DUBLIN, Sept. 22, 2020 /PRNewswire/ -- The "Respiratory Inhalers Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The respiratory inhalers market by revenue is expected to grow at a CAGR of over 9% during the period 2019-2025.

The following factors are likely to contribute to the growth of the respiratory inhalers market during the forecast period:

• Increase in Usage of Smart Inhaler
• Introduction of Soft Mist Inhalers
• Increase in Target Population
• Surge in Inhalers Usage due to COVID-19

The global respiratory inhalers market is one of the steadily growing segments in the medical devices market. The steady growth can be attributed to the growing prevalence of asthma, COPD, and cystic fibrosis and the outbreak of the COVID-19 pandemic. The prevalence of COPD and other respiratory disorders demanding inhalers has increased at a significant rate over the last few years across the globe. According to the WHO, COPD is expected to emerge as the third leading cause of death across the world by 2025.

The increasing incidence of respiratory diseases and the growing demand for treatment options for respiratory disorders are fueling the market growth of therapeutic respiratory care devices such as inhalers. Further, the presence of established infrastructure in several countries of North America, Europe, and APAC, coupled with the availability of well-developed technologies that allow early implementation of advanced inhalation technologies, increases the demand for inhalers. Favorable government initiatives in emerging economies toward improvising standard healthcare infrastructure and increased focus on healthcare expenditure are also aiding to focus on offering high-quality healthcare services.

Global Respiratory Inhalers Market Highlights

The global respiratory inhalers market research report includes a detailed segmentation by products, patient, distribution channel, and geography. The metered dosage inhaler segment is expected to over 2.5 billion by 2025 due to the outbreak of COVID-19, which has led to the increased usage of inhalers among respiratory disease patients. Pressurized metered dosage inhalers (pMDIs) and dry-powder inhalers (DPIs) are commonly used among end-users. pMDIs are mostly used among developing and underdeveloped countries due to their low price and easy availability in pharmacies.

The respiratory inhalers market is segmented into pediatric and adults age groups. In. 2019, the adult segment accounted for the share of 68%, and the pediatric population constituted a share of 32% in the respiratory inhalers market. The adult population is widely exposed to several environmental risk factors such as air and workplace pollutions and the consumption of tobacco. This contributes to the high share of the adult population in the market.

While the prevalence of asthma is increasing in several countries, multiple factors are affecting the incidence of asthma in the adult population. With the eruption of the COVID-19 pandemic, the number of adults infected is higher than pediatric and neonates populations. Therefore, the demand for inhalers has gone drastically up across the globe due to the spread of the virus.

North America has dominated the global inhalers market, and dominance is mainly due to the increase in the prevalence of several respiratory diseases. The US has been the earliest adopters of the latest inhalers technology to reduce the rate of COPD. In North America, both the US and Canada experienced a large-scale adoption of these devices over the last decade. The rise in pollution rates, along with the growing number of cases of respiratory troubles, is one of the major reasons that boosts the overall demand in the region.

Besides, since the outbreak of the COVID pandemic, the need for inhalers has grown significantly in ICUs and emergency rooms. A large population on ventilators are supported with inhalers for increased effectiveness of the medicine. Although the market is expected to grow at a slower rate than other regions, there is a surge in demand for inhalers in the region, especially in the US owing to the COVID-19 pandemic. The country will witness growth as the national health spending is projected to grow at an average annual rate of over 5% during the period 2019-2028, reaching $6.2 trillion by 2028.

GSK, Novartis, BOEHRINGER INGELHEIM, Cipla, and AstraZeneca are the key players dominating the global inhalers market. Although large vendors dominate the market, they are witnessing heavy competition from regional and local companies from India, China, Italy, and Germany. Many regional vendors are also offering cost-effective products in Europe, APAC, and the Middle East & Africa regions.

Competitive Landscape

• Cipla
• GSK
• Novartis
• Boehringer Ingelheim
• Astrazeneca

Key Company Profiles

• Glaxosmithkline
• Novartis
• Boehringer Ingelheim
• Cipla
• AstraZeneca

Other Prominent Vendors

• Propeller Health
• Beximco Pharmaceuticals
• H&T Presspart
• Cohero Health
• CHIESI Farmaceutici
• Mundipharma
• 3M
• HELTMAN Medikal
• Adherium
• Luckys Pharma
• Amiko Digital Health
• Teva Pharmaceutical Industries
• Findair Sp. z o. o.
• Vectura Group

For more information about this report visit https://www.researchandmarkets.com/r/m5xkto

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets